Durvalumab antibody | AbD41313ia

Human anti Durvalumab

Product Type
Monoclonal Antibody
Clone
AbD41313ia
Isotype
IgG1
Specificity
Durvalumab

Product Code Applications Pack Size List Price Your Price Qty
New HCA360
Datasheet Datasheet Datasheet
SDS Safety Datasheet SDS
E 0.1 mg loader
List Price Your Price
loader
Search for Batch Specific Datasheets

Human Anti-Durvalumab Antibody, clone AbD41313ia is a paratope specific, inhibitory anti-idiotypic antibody (Type 1) that specifically recognizes the free human monoclonal antibody drug durvalumab. The antibody does not recognize free PD-L1 nor durvalumab in complex with PD-L1.

Clone AbD41313ia is a fully human recombinant monoclonal antibody with IgG1 isotype and can be used as a surrogate positive control or reference standard in an anti-drug antibody (ADA) assay. This antibody has a monovalent intrinsic affinity of 14 nM, and is one of two antibodies with different affinities offered for ADA assays.

ADA bridging ELISA

HCA360 may also be used as the detection antibody together with the Anti-Durvalumab monovalent Fab antibody TZA004, as capture antibody in a pharmacokinetic (PK) assay to measure free durvalumab captured via immobilized PD-L1.

PK bridging ELISA

Durvalumab (Imfinzi) is a human IgG1/kappa antibody with allotype G1m3. The CH2 domain was engineered with three amino acid substitutions (L238F, L239E, P335S) to reduce the Fc-mediated effector functions to prevent depletion of PD-L1+ T-cells. It was first approved for previously treated patients with advanced bladder cancer. It was later approved for the treatment of unresectable stage 3 NSCLC (Non-Small Cell Lung Cancer) and ES-SCLC. Durvalumab binds to PD-L1 to block the interaction with the inhibitory T cell receptor PD-1. This blockade removes the suppression of T-cells that are specific for MHC-1-presented neoepitopes on tumor cells. Removal of this inhibitory signal leads to the release of granzymes and perforins by the activated T-cells, and finally to the destruction of the tumor cells.

View a summary of all anti-durvalumab antibodies

Target Species
Drug
Product Form
Human IgG1 antibody (lambda light chain) selected from the HuCAL phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
Preparation
Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.01% Thiomersal
Immunogen
Durvalumab
Affinity
The intrinsic affinity of the monovalent form of Human anti Durvalumab antibody, clone AbD41313ia is KD = 14 nM as measured by real time, label free molecular interaction analysis on immobilized Durvalumab.
Approx. Protein Concentrations
Antibody concentration 0.5 mg/ml
ELISA Matched Pair(s)
ELISA Matched Pair-Capture Antibody: TZA004
Regulatory
For research purposes only
Guarantee
12 months from date of despatch
Acknowledgements
This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.
Imfinzi is a trademark of Medimmune/AstraZeneca using Abgenix's XenoMouse technology.

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
ELISA
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual.
ELISA
This product may be used in a direct or indirect ELISA or as a detection reagent for durvalumab in a PK bridging ELISA together with TZA004 (AbD41327) as the capture reagent. It can also be used to develop and calibrate anti drug antibody (ADA) assays to measure the ADA response in patient sera together with HCA359

Protocol: ADA bridging ELISA.

Description Product Code Applications Pack Size List Price Your Price Quantity
LYNX Rapid HRP Antibody Conjugation Kit LNK002P CJ 3 Conjugations For 400µg Antibody
List Price Your Price
Description LYNX Rapid HRP Antibody Conjugation Kit
Hispec Assay Diluent BUF049A E IY 50 ml
List Price Your Price
Description Hispec Assay Diluent
Human anti Durvalumab HCA359 E 0.1 mg loader
List Price Your Price
loader
Description Human anti Durvalumab

Licensed Use
For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
View more products with Durvalumab specificity

Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"

View all Anti-Drug Products